Sobi-Innate pact elevates lacutamab for CTCL toward accelerated approval
Aug 10, 2026, 2:36 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The upfront $75M, milestone potential, and royalties introduce tangible value for SOBI, plus exclusive global rights and an acceleration pathway could meaningfully shift the risk-reward on lacutamab in CTCL. Antitrust clearance risk caps immediate upside; however, the deal creates a defensible, revenue-generating option should regulatory approvals be achieved.
AI summary
What happened, with direct paths to the underlying reporting
Swedish Orphan Biovitrum (SOBI) and Innate Pharma unveiled a strategic lacutamab deal to initiate TELLOMAK-3 in CTCL, targeting accelerated Sézary syndrome approval. Sobi would gain exclusive global rights on approval and could obtain full rights after a positive Phase 3; upfront and milestone payments total up to about $580M with royalties. Closing depends on antitrust clearance.
Strategic partnership to license lacutamab in CTCL. TELLOMAK-3 to seek accelerated Sézary approval.
Closing payment: $75M to Innate. Up to $40M near-term milestones; up to $465M rights option.
Sobi gets exclusive global rights after accelerated approval. Full rights possible after positive Phase 3.
Lacutamab is first-in-class anti-KIR3DL2 with FDA Fast Track and EMA PRIME designations.
TELLOMAK-3 targets Sézary syndrome and MF; pivotal readout expected.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
